Please login to the form below

Not currently logged in
Email:
Password:

mis-marketing

This page shows the latest mis-marketing news and features for those working in and with pharma, biotech and healthcare.

Sandoz admits antitrust crime, pays $195m in penalties

Sandoz admits antitrust crime, pays $195m in penalties

Cohen, data manipulation involving its gene therapy Zolgensma and bribery and mis-marketing allegations in several countries including the US.

Latest news

  • Purdue Pharma files for bankruptcy after opioid settlement Purdue Pharma files for bankruptcy after opioid settlement

    The company will also be permanently bound to injunctive relief, which includes marketing restrictions on the sale and promotion of opioids. ... In  August, Johnson &Johnson became the first company found liable for opioid medication mis-marketing, and

  • J&J found liable in first opioid mis-marketing verdict J&J found liable in first opioid mis-marketing verdict

    Nevertheless,  the court's decision could set a precedent for other drug companies involved in marketing opioids during this period, unless it is reversed on appeal. ... marketing to disseminate the messages that pain was under-treated and ‘there was

  • Reckitt hammered by $1.4bn opioid settlement bill Reckitt hammered by $1.4bn opioid settlement bill

    The settlement is the largest recovery for opioid drug mis-marketing in US history, according to the Department of Justice, and is made up of $647m to the federal government, $700m ... Drug manufacturers marketing products to help opioid addicts are

  • Double win for J&J's schizophrenia franchise Double win for J&J's schizophrenia franchise

    Johnson &Johnson (J&J) will not have to pay a $1.2bn penalty for alleged mis-selling of its schizophrenia drug Risperdal in the US, according to a court ruling. ... Two years ago, a $1.2bn fine was levied on J&J and its Janssen Pharma unit after a jury

  • Takeda CEO admits to Blopress mis-marketing Takeda CEO admits to Blopress mis-marketing

    The mis-marketing stemmed from a trial initially reported at a medical conference in 2006 and subsequently published in the journal Hypertension two years later, according to Hasegawa. ... The incident comes amid increased scrutiny of pharma marketing

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics